Please ensure Javascript is enabled for purposes of website accessibility

Can Cara Therapeutics Stock Bounce Back?

By Keith Speights - Jul 11, 2017 at 3:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cara Therapeutics lost over half of its market cap in less than two weeks. Can the stock recover?

It was only a few weeks ago that Cara Therapeutics (CARA -2.47%) stock was hitting all-time highs. The company had announced good news from its independent data monitoring committee's interim assessment for a late-stage study of intravenous (IV) CR845 in treating post-operative pain. More potential catalysts were on the way. Things seemed to be looking up for the clinical-stage biotech.

Note the use of past tense in all those statements. Results from a phase 2 study of an oral version of CR845 in treating chronic pain for patients with osteoarthritis of the hip or knee were underwhelming. Cara stock has plunged more than 50% since the announcement. Can it bounce back?

Man looking at arrow going down through floor

Image source: Getty Images.

How bad was the bad news?

For Cara's market cap to lose half of its value, you'd think the results from the phase 2 study were totally devastating. Actually, though, there were some positives. The highest dosage given to patients in the study (5 mg) did produce a statistically significant reduction in pain scores for hip patients compared to placebo. Two-thirds of hip patients taking oral CR845 didn't require a rescue medication after eight weeks of treatment compared to 43% for the placebo group.

Also, oral CR845 appeared to have a good overall safety profile. There were no drug-related serious adverse events. The most common side effects that did occur -- constipation, dizziness, and dry mouth -- were prevalent in fewer patients than a commonly prescribed opioid pain medication, Oxycontin-IR.

That's the good news. The bad news is that oral CR845 proved no more effective than placebo at lower dosages. And Cara didn't say much about how the drug performed with knee patients.

However, we do know two things. First, the reduction in pain scores was quite lower than for hip patients, since there was a 35% reduction in mean joint pain score for all patients. Second, more knee patients completed treatment with placebo than they did with oral CR845, whereas the completion rates were similar for hip patients on placebo and CR845.

What's next written on paper

Image source: Getty Images.

Where Cara goes from here

By no means is Cara throwing in the towel for its oral version of CR845. The company intends to initiate a phase 2 adaptive trial with some key changes. Cara is going to increase the tablet strength to 10 mg. It will also increase hip patient exposure in the study. Both seem like smart things to do.

Cara also plans to request a "type C" meeting with the U.S. Food and Drug Administration (FDA) to discuss next steps. The FDA has three categories of meetings with drugmakers. Type A meetings are focused on helping a stalled program proceed. Type B meetings are held at key junctures such as before an investigational new drug application (NDA) is submitted, at the end of phase 1, or at the end of phase 2 and the beginning of phase 3 testing. The type C meeting that Cara requested is for any other type of meeting.

The company also awaits completion of two late-stage studies for its IV version of CR845. Cara expects the study targeting post-operative pain to complete by the end of 2017. The other study, which is focused on treatment of uremic pruritis (itching) in patients on hemodialysis, is scheduled to wrap up early next year.

Question mark sign in middle of road

Image source: Getty Images.

Is a rebound likely?

There's no way to know for sure how the late-stage studies of IV CR845 will turn out. However, earlier results hint at a reasonable chance of success.

Clearly, though, the potential market for an oral form of CR845 would be tremendously important for Cara Therapeutics. At this point, it's really up in the air as to what happens next for oral CR845. There's a lot riding on Cara's discussion with the FDA. 

Can Cara rebound? I think the short answer is "yes." Good news from the IV CR845 studies or from the FDA should give a nice boost to the stock.

But will Cara stock regain all the ground that it's lost in the last couple of weeks? My guess is that's not likely to happen in the near future. Over time, however, if higher doses of oral CR845 are found to be effective and safe, the promise seen in Cara earlier this year could still be realized. For now, that's a big "if."

Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cara Therapeutics, Inc. Stock Quote
Cara Therapeutics, Inc.
CARA
$11.46 (-2.47%) $0.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.